ORIGINAL RESEARCH

Value of Ultrasound Combined with Immunohistochemistry Evaluation of Central Lymph Node Metastasis for the Prognosis of Papillary Thyroid Carcinoma

Xiaohua Yao [ID][1],*
Ying Meng [ID][1],*
Runsheng Guo [ID][2]
Guofeng Lu [ID][3]
Lin Jin [ID][1]
Yingchun Wang [ID][1]
Debin Yang [ID][1]

[1]Departments of Ultrasound, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201800, People's Republic of China; [2]Departments of General Surgery, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201800, People's Republic of China; [3]Departments of Pathology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201800, People's Republic of China

*These authors contributed equally to this work

Correspondence: Debin Yang
Department of Ultrasound, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, People's Republic of China
Tel +86-021-67073318
Email yyddrr123@163.com

Background: Papillary thyroid carcinoma (PTC) is often accompanied by cervical lymph node metastasis (LNM). The accuracy of the preoperative ultrasound diagnosis of central LNM (CLNM) is limited. LNM is a high-risk factor for local recurrence and may affect the prognosis. Factors not directly related to tumor proliferation are used for risk assessment in the tumor-node-metastasis (TNM) staging system for thyroid cancer. The present study aimed to investigate the value of ultrasound and immunohistochemistry in predicting the presence of CLNM and the prognosis of PTC.

Patients and Methods: The ultrasound and immunohistochemistry features of 303 patients with first-ever PTC and who underwent surgery between 01/2014 to 12/2016 were analyzed, as well as the prognosis of the patients. Univariable and multivariable analyses were carried out to determine the risk factors of CLNM and recurrence.

Results: Among 303 patients, 125 (41.3%) were pathologically confirmed with CLNM. Multivariable analysis showed that multifocality, taller-than-wide shape, grade III–IV blood flow, capsular invasion, Ki-67 >10%, p53 ≥5%, T2 or T3 stages were independent risk factors for CLNM. The median follow-up was 56 months. Cox regression analysis showed that age ≥55 years, maximum tumor diameter >20 mm, multifocality, capsular invasion, Ki-67 5–10%, Ki-67 >10%, p53 ≥5%, T3 stage and N1a stage were independent risk factors for PTC recurrence. The Kaplan–Meier showed that recurrence-free survival (RFS) was different according to age (P=0.017), tumor size multifocality, capsular invasion, Ki-67, p53, T stage and N stage (all P<0.001).

Conclusion: For PTC with rich blood flow, taller-than-wide shape, multifocality, capsular invasion, p53 ≥5%, Ki-67 >10%, T2 or T3 stages prophylactic CLNM dissection might be indicated. Age≥55 years, maximum tumor diameter >20 mm, multifocality, capsular invasion, high Ki-67, p53 ≥5%, T3 and N1a stages affected the clinical outcome.

Keywords: papillary thyroid carcinoma, ultrasonic features, Ki-67, p53, central lymph node metastasis, prognosis

Introduction

Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid and generally has a good prognosis. Nevertheless, some PTCs are invasive and are associated with lymph node metastasis (LNM), extra-thyroid extension (ETE), local recurrence, distant metastasis, or even death.[1–3] Among patients with PTC, 30–80% exhibit neck LNM at diagnosis, especially in the central region.[4] Even in

slow-growing PTCs, about 30% have central LNM (CLNM).[5,6] LNM is a high-risk factor for local recurrence and may affect prognosis.[1,7,8] Ultrasound is among the most commonly used imaging methods for the tumor-node-metastasis (TNM) staging of PTC.[9] Ultrasound staging can show tumor size, ETE, LNM, and other features noninvasively, and those characteristics might affect the operation.[9] Notwithstanding, there are limitations in the evaluation of CLNM by ultrasound before PTC surgery. The sensitivity of CLNM diagnosis is <50%,[10,11] and the accuracy is lower than that of LNM in the lateral cervical region and thyroid capsule invasion.[12,13]

The 2015 American Thyroid Association (ATA) guidelines pointed out that the initial treatment goal of PTC is to improve the survival and achieve accurate staging and risk stratification in order to reduce the incidence of treatment-related complications and postoperative recurrence.[1] Nevertheless, currently, there is no reliable method to accurately predict the progression of papillary thyroid microcarcinoma (PTMC). Moreover, no factors directly related to tumor proliferation activity are used for risk assessment in the TNM staging system for thyroid cancer. Tumor proliferative activity is critical for biological evaluation, including prognosis.[14] Ki-67 is a key marker that indicates cell proliferation and a vital index to evaluate the recurrence and metastasis of breast cancer,[15] cervical cancer,[16] colorectal cancer,[17] and lung cancer.[18] A meta-analysis showed that Ki-67 might have an impact on the prognosis of non-Chinese thyroid cancer patients.[19] p53 protein is a tumor suppressor protein that promotes the transformation and excess proliferation of cancer cells.[20] The high expression of p53 is related to PTC ETE and LNM, albeit without statistical significance.[21] Whether Ki-67 and p53 can predict the prognosis of PTC with high differentiation and inactive malignant behavior needs to be investigated further. Positive CK19 staining has been observed in PTC and is recognized as a reliable marker for PTC,[22,23] but its value prognosis of PTC uncertain.[24–28]

Therefore, the present study aimed to explore the risk factors of CLNM and recurrence by the retrospective analysis of the ultrasonic features and immunohistochemical indexes of primary PTC tumors.

Patients and Methods
Patients Selection
This retrospective analysis included 303 cases of thyroid PTC, who underwent surgery at the Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, from January 2014 to December 2016, and with complete ultrasound images and histopathological data. This study was approved by the Ethics Committee of Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Science (No. JDKW-2016-W12). This study was conducted in accordance with the Declaration of Helsinki.

The inclusion criteria were: 1) PTC was confirmed by postoperative pathology; 2) all patients underwent central lymph node dissection (CLND); the operation methods were thyroidectomy, isthmectomy, and ipsilateral CLND for unilateral tumor, and total thyroidectomy plus bilateral CLND for bilateral tumor; 3) there was no evidence of cervical lymph node metastasis or distant metastasis on preoperative ultrasound and computed tomography (CT); and 4) the patients were treated with thyrotropin after surgery. At least two experienced pathologists examined the lymph node specimens to determine LNM. The patients were routinely followed at 3 months, 6 months, and 1 year after the first operation, and then every year. Patients were examined by ultrasound, chest X-ray, or computed tomography (CT). LNM occurrence, recurrence of residual thyroid, and distant metastasis, screened by postoperative pathology, biopsy, or imaging methods, were defined as recurrence.

Evaluation of Ultrasonic Features
GE Logiq E8, Toshiba Aplio 500, and Philips IU22 ultrasound diagnostic systems and high-frequency linear array probes (5–12 MHz) were used to assess the number, size, echogenicity, border, margin, shape, microcalcification, blood flow, and capsular invasion of the tumor. If the patient had multiple lesions, the largest one was selected as the observation object. The tumors were divided into three groups: the largest diameter <10 mm, 10–20 mm, and >20 mm. The blood flow of the tumor was graded by the Adler semiquantitative method,[29] according to the following criteria: Grade I: no obvious blood flow, indicating the absence of obvious blood flow signal inside the tumor; Grade II: small amount of blood flow, showing 1–2 punctate or short rod blood flow signals in the tumor; Grade III: moderate blood flow, showing 3–4 punctate blood flow signals or one long strip of blood flow signal in the tumor; and Grade IV: abundant blood flow, showing >5 punctate blood flow signals, >2 long strip blood flow signals, reticular blood flow signals, or dendritic blood flow signals. At ultrasound, when it was observed that

the tumor was in contact with >25% of the adjacent thyroid capsule, or the thyroid capsule was disrupted by the tumor, or the soft tissue around the thyroid gland was invaded, it was defined as capsular invasion.[6,30,31]

Evaluation of Immunohistochemistry Indexes

All PTC samples were fixed with 10% neutral formalin, treated routinely, embedded in paraffin, sectioned continuously into 4-µm-thick sections, dewaxed in xylene, hydrated in an ethanol gradient, repaired for antigens at high pressure and temperature for 90 s, incubated with hydrogen peroxide at room temperature for 10 min, thoroughly rinsed and finally used for hematoxylin and eosin staining and immunohistochemistry (all antibodies were from Shanghai Changjia Biotechnology Co., Ltd., Shanghai, China). The primary antibodies were incubated for 60 min, and the secondary antibodies were incubated for 20 min. The protein of interest was revealed using DAB, and the slides were counterstained with hematoxylin. The sections were dehydrated in an ethanol gradient, treated with xylene, and sealed in neutral resin. PBS was used instead of an antibody as negative control. The indexes of CK19, p53 (p53-antibody anti-mutant p53), and Ki-67 were observed under a light microscope. The percentages of positive cells were calculated as: Percentage of positive cells = number of positive cells/the total number of cells × 100%. CK19 expression was divided into four groups (5%, 5%-25%, 25%-75%, and >75%).[32] p53 expression was divided into two groups according to the proportion of nuclear-positive cells <5% and ≥5%.[21] Ki-67 expression was divided into three groups (5%, 5–10%, and >10%).[14,33]

Statistical Analysis

The data were analyzed using SPSS 24.0 and GraphPad Prism 7.0. The age and maximum diameter of the tumor were expressed as means ± standard deviations ($\bar{x} \pm s$). The age groups, sex, ultrasonic characteristics and immunohistochemical data were expressed as frequency (%). The risk factors of CLNM were determined by conditional forward logistic regression analysis. The multivariable analyses were carried out using the variables with P<0.10 in the univariable analyses. Multivariable Cox regression analysis was used to determine the risk factors for recurrence. The Kaplan–Meier method and Log rank tests were used to compare recurrence-free survival (RFS) between groups. P<0.05 indicated statistical significance.

Results

Patient Characteristics

The clinical data of 303 patients with PTC are summarized in Table 1. Their average age was 47.1±13.1 years of age, and the maximum tumor diameter was 13.3±7.3 (4–41) mm. There were 194 patients with a single tumor (64.0%) and 60 patients with unilateral multifocal tumors (19.8%); they all underwent thyroidectomy, isthmectomy, and ipsilateral CLND. On the other hand, 49 patients with bilateral multifocal tumors (16.2%) underwent total thyroidectomy and bilateral CLND. Among the 303 patients, CLNM was confirmed by pathology in 125 (41.3%) patients. No patient received radioiodine. The entire PTC cohort was followed for at least 3 years. The median follow-up was 56 (6–72) months. Thirty-three patients (10.9%) had a recurrence, including eight cases of residual thyroid recurrence, 22 of distant LNM, and three of both local and LNM. No deaths were not recorded. Figure 1 shows the ultrasound and histological characteristics of a typical case.

Correlation Between CLNM and Ultrasound Features and Immunohistochemical Indexes

Univariable analyses showed that CLNM was associated with the irregular shape of the primary tumor, taller-than-wide shape, grade III–IV blood flow, multifocality, capsular invasion, Ki-67, p53, and T stage (Table 2). Multiple logistic regression analysis was carried out for the indexes with P<0.10 in the univariable analyses. The results showed that taller-than-wide shape, blood flow grade III–IV, multifocality, capsular invasion, Ki-67 >10%, p53 ≥5%, T2 stage, and T3 stage were independently associated with CLNM. The odds ratios (ORs) (95% confidence intervals (CIs)) of the above factors were 2.788 (1.416–5.486), 2.938 (1.506–5730), 2.908 (1.368–6.184), 4.393 (1.200–16.089), 5.320 (1.634–17.319), 4.160 (1.947–8.888), 2.556 (1.096–5.961), and 8.500 (1.349–53.563), respectively (Table 2).

Correlation Between Ultrasound Features and Immunohistochemical Indexes and Postoperative Recurrence

Univariable analyses showed that recurrence was associated with age, maximum tumor diameter, taller-than-wide shape, grade III–IV blood flow, multifocality, capsular invasion, Ki-67, p53, T stage, and N stage. Multivariable

Table 1 Demographics and Clinical Characteristics of the 303 PTC Patients

Characteristics	n=303
Age, years	47.1±13.1
Age groups, n (%)	
<55years	224 (73.9%)
≥55 years	79 (26.1%)
Sex, n (%)	
Female	224 (73.9%)
Male	79 (26.1%)
Size on US, mm	13.3±7.3
Size groups, n (%)	
<10 mm	103 (34.0%)
10–20 mm	144 (47.5%)
>20 mm	56 (18.5%)
Surgery, n (%)	
Total thyroidectomy+CLND	49 (16.2%)
Thyroidectomy and isthmectomy + CLND	254 (83.8%)
Multifocality, n (%)	
Single	194 (64.0%)
Ipsilateral	60 (19.8%)
Bilateral	49 (16.2%)
US features	
Echogenicity, n (%)	
Isoechoic/Hyperechoic	13 (4.3%)
Hypoechoic/Marked hypoechoic	290 (95.7%)
Border, n (%)	
Clear	90 (29.7%)
Obscure	213 (70.3%)
Margin, n (%)	
Regular	133 (43.9%)
Irregular	170 (56.1%)
Shape, n (%)	
Wide than taller	159 (52.5%)
Taller than wide	144 (47.5%)
Microcalcification, n (%)	
No	112 (37.0%)
Yes	191 (63.0%)
Blood flow, n (%)	
I–II	199 (65.7%)
III–IV	104 (34.3%)
Capsular invasion, n (%)	
No	245 (80.9%)
Yes	58 (19.1%)
Immunohistochemical index	

(*Continued*)

Table 1 (Continued).

Characteristics	n=303
Ki-67, n (%)	
<5%	203 (70.0%)
5%-10%	77 (25.4%)
>10%	23 (7.6%)
CK19, n (%)	
<25%	52 (17.2%)
25–50%	201 (66.3%)
50–75%	35 (11.5%)
>75%	15 (5.0%)
p53, n (%)	
<5%	151 (49.8%)
≥5%	152 (50.1%)
T stage, n (%)	
T1	217 (71.6%)
T2	43 (14.2%)
T3	43 (14.2%)
T4	0
N stage, n (%)	
N0	178 (58.7%)
N1a	125 (41.3%)
M stage, n (%)	
M0	303 (100%)
M1	0
Recurrence, n (%)	33 (10.9%)

Cox regression analysis showed that age ≥55 years, the largest tumor diameter >20 mm, multifocality, capsular invasion, Ki-67 5%-10%, Ki-67 >10%, p53, T3 stage, and N1a stage were independently associated with recurrence. The hazard ratio (HR) (95% CI) of the above factors was 2.258 (1.069–4.770), 6.339 (1.832–21.929), 2.503 (1.115–5.618), 6.915 (2.974–16.078), 3.631 (1.324–9.961), 5.343 (1.745–16.365), 3.896 (1.252–12.118), 7.220 (2.429–21.467), and 9.368 (1.196–73.393), respectively (Table 3).

Survival Analysis After PTC

The survival analyses are shown in Figure 2. The Kaplan–Meier analysis showed that age (≥55 and <55 years of age; P=0.017; Figure 2A), tumor size (P<0.001; Figure 2B), multifocality (P<0.001; Figure 2C), capsular invasion (P<0.001; Figure 2D), Ki-67 (P<0.001; Figure 2E), p53 (P<0.001; Figure 2F), T stage (P<0.001; Figure 2G), and N stage (P<0.001; Figure 2H) differed significantly in RFS. The RFS was 95.1%, 89.6%, and 76.8% in patients with tumor

Figure 1 A 36-years-old woman with PTC. (**A**) Preoperative ultrasound images showing that the size of the tumor was about 7.8×12.0 mm^2, the boundary was clear, the morphology was not regular, strong punctate echo (microcalcification) was detected, and the thyroid capsule echo was interrupted (arrow). (**B**) Abundant blood flow signals in the tumor. (**C**) Postoperative pathology was confirmed to be PTC, hematoxylin-eosin (HE) ×200. (**D**) The number of CK19-positive cells was nearly 100%, streptavidin-peroxidase (SP) ×200. (**E**) Ki-67 is about 15%, SP ×200. (**F**) p53-positive cells are about 10% (+), SP ×200. (**G**) After 6 months, the ultrasound showed suspicious LNM in the right lateral jugular vein (V area), about 3×5 mm^2 in size (arrow). (**H**) Confirmed by fine-needle aspiration (FNA) as LNM (arrow), H-E ×200.

maximum diameter <10 mm, 10–20 mm, and >20 mm, respectively (<10 vs 10–20 mm, P=0.116; <10 vs >20 mm, P<0.001; 10–20 vs >20 mm, P=0.014). The RFS of single and multifocal tumors was 95.4% and 78.0%, respectively (P<0.001), while it was 96.3% and 58.6% (P<0.001) in patients with and without capsule invasion. Furthermore,

the RFS of patients with Ki-67 <5%, 5–10%, and 10% was 96.6%, 77.9%, and 60.9%, respectively (<5% vs 5–10%, P<0.001; <5% vs >10%, P<0.001; 5%-10% vs >10%, P=0.042). The RFS of patients with p53 <5% and p53 ≥5% was 97.4% and 80.9%, respectively (P<0.001). Additionally, the RFS of patients of T1, T2, and T3 stages were 97.7%,

Table 2 Univariable and Multivariable Analyses Results of Ultrasound Features, Immunohistochemical Indexes and CLNM

Characteristics	CLNM+ (n=125)	CLNM- (n=178)	Univariable Analysis		Multivariable Analysis	
			OR (95% CI)	P-value	OR (95% CI)	P-value
Age					N/A	
<55 years	94 (75.2%)	130 (73.0%)	1			
≥55 years	31 (24.8%)	48 (27.0%)	0.893 (0.529–1.508)	0.672		
Sex					N/A	
Female	90 (72.0%)	134 (75.3%)	1			
Male	35 (28.0%)	44 (24.7%)	1.184 (0.705–1.988)	0.522		
Size groups					N/A	
<10 mm	32 (25.6%)	71 (39.9%)	1			
10–20 mm	62 (49.6%)	82 (46.1%)	1.678 (0.986–2.856)	**0.057**		
>20 mm	31 (24.8%)	25 (14.0%)	2.751 (1.405–5.388)	**0.003**		
Echogenicity					N/A	
Isoechoic/Hyperechoic	5 (4.0%)	8 (4.5%)	1			
Hypoechoic/Marked hypoechoic	120 (96.0%)	170 (95.5%)	2.743 (0.864–8.711)	0.834		
Border					N/A	
Clear	30 (24.0%)	60 (33.7%)	1			
Obscure	95 (76.0%)	118 (66.3%)	1.610 (0.962–2.694)	0.070		
Margin					N/A	
Regular	46 (36.8%)	87 (48.9%)	1			
Irregular	79 (63.2%)	91 (51.1%)	1.642 (1.029–2.620)	**0.038**		
Shape						
Wide than taller	48 (38.4%)	111 (62.4%)	1		1	
Taller than wide	77 (61.6%)	67 (37.6%)	2.658 (1.659–4.257)	**<0.001**	2.788 (1.416–5.486)	**0.003**
Microcalcification					N/A	
No	39 (31.2%)	73 (41.0%)	1			
Yes	86 (68.8%)	105 (59.0%)	1.533 (0.947–2.483)	0.082		
Blood flow						
I–II	63 (50.4%)	136 (76.4%)	1		1	
III–IV	62 (49.6%)	42 (23.6%)	3.187 (1.947–5.215)	**<0.001**	2.938 (1.506–5730)	**0.002**
Capsular invasion						
No	76 (60.8%)	169 (94.9%)	1		1	
Yes	49 (39.2%)	9 (5.1%)	12.107 (5.659–25.903)	**<0.001**	4.393 (1.200–16.089)	**0.025**
Multifocality						
No	56 (44.8%)	138 (77.5%)	1		1	
Yes	69 (55.2%)	40 (22.5%)	4.251 (2.583–6.996)	**<0.001**	2.908 (1.368–6.184)	**0.006**
Ki-67						
<5%	63 (50.4%)	140 (78.7%)	1		1	
5%-10%	45 (36.0%)	32 (18.0%)	3.125 (1.817–5.374)	**<0.001**	1.367 (0.663–2.821)	0.397
>10%	17 (13.6%)	6 (0.3%)	6.296 (2.370–16.727)	**<0.001**	5.320 (1.634–17.319)	**0.006**
CK19					N/A	
<25%	18 (14.4%)	34 (19.1%)	1			
25–50%	85 (68.0%)	116 (65.2%)	1.384 (0.733–2.615)	0.317		
50–75%	15 (12.0%)	20 (11.2%)	1.417 (0.588–3.416)	0.438		

(Continued)

Table 2 (Continued).

Characteristics	CLNM+ (n=125)	CLNM- (n=178)	Univariable Analysis		Multivariable Analysis	
			OR (95% CI)	P-value	OR (95% CI)	P-value
>75%	7 (5.6%)	8 (4.5%)	1.653 (0.516–5.294)	0.398		
p53						
<5%	31 (24.8%)	120 (67.4%)	1		1	
≥5%	94 (75.2%)	58 (32.6%)	6.274 (3.757–10.477)	**<0.001**	4.160 (1.947–8.888)	**<0.001**
T stage						
T1	65 (19.8%)	152 (80.2%)	1		1	
T2	20 (48.8%)	23 (51.2%)	3.617 (1.653–7.915)	**0.001**	2.556 (1.096–5.961)	**0.030**
T3	40 (93.2%)	3 (6.8%)	51.789 (14.448–185.636)	**<0.001**	8.500 (1.349–53.563)	**0.023**

Note: Bold P-values are statistically significant (P<0.05).
Abbreviations: OR, odds ratio; CI, confidence interval; N/A, not available.

86.1%, and 38.8% (P<0.001); those of N0 and N1a were 99.4% and 74.4% (P<0.001), respectively (Figure 2).

Discussion

Although preoperative ultrasound is routinely used for thyroid cancer, and acute lymph node staging, the accuracy of CLNM ultrasound is not high. In this study, the precise diagnosis of PTC combined with factors directly related to tumor proliferation activity was carried out for risk assessment, and the factors independently associated with CLNM and prognosis were identified, which could be helpful to subdivide high-risk or low-risk PTC. The 2015 ATA guidelines recommend CLND for patients with PTC and suspected LNM or advanced stage metastasis.[1] Nevertheless, preventive CLND for patients without evidence of lymph node metastasis is still controversial because of the risks of complication and morbidity. Because CLND has uncertain efficacy and high risk of complications,[34,35] reoperation of PTC recurrence may significantly increase the surgical complications and affect the quality of life of the patients.[36] Therefore, identifying the specific risk factors of CLNM is crucial. Some recent studies tried to predict CLNM in patients with thyroid cancer based on ultrasound features, but the specificity is low.[6,37] Hence, in the present study, we included indicators such as ultrasound features and immunohistochemistry, for an in-depth analysis of the factors associated with CLNM. The results showed that capsule invasion was the strongest factor among ultrasonic features (OR=4.493), which was consistent with the previous results.[5,6] Taller-than-wide shape and blood flow were reported by Xu et al[6] but the present study reached different conclusions, possibly because of case selection since their research was limited to PTMC.

The cases with taller-than-wide shape accounted for 60.7%,[6] which was significantly higher than in the present study (47.5%). In addition, PTMC is characterized by the lack of blood supply due to the lack of internal neovascularization.[38] High contrast-enhanced or iso-enhanced contrast-enhanced ultrasound is an index to predict CLNM,[39] supporting the present study. Multifocality has been recognized as a risk factor for LNM,[5,40] and this was observed here. Since the thyroid is a rich network of lymphatic channels, multifocal tumors increase the chance of intraglandular metastasis and LNM.[5] T2 and T3 tumors were associated with CLNM, but 31.1% of the patients in the <10-mm group still had CLNM, indicating that smaller tumors are still invasive. This is supported by the fact that PTC size is indeed associated with metastases.[41] In addition, we confirmed that p53 ≥5% and Ki-67 >10% were independent risk factors of LNM, but CK19 was not related to CLNM. The usefulness of CK19 as a postsurgical prognostic factor of PTC in various populations has so far yielded conflicting results.[24–28] Some studies showed that the expression of Ki-67 and p53 was not related to tumor size.[42,43] Therefore, the evaluation of the proliferation activity of the tumor cell is more reliable for determining the biological behavior rather than relying on tumor size alone. Indeed, a tumor of 10 mm, for example, can be the results of an aggressive tumor that grew over a few months or of an indolent tumor that grew over a few years. The biological markers might indicate the aggressiveness of a tumor.

PTC is characterized by low invasiveness, with a 10-year survival rate of >90%, but as high as 22–30% of patients show relapse, and most of them occur within 3 years.[44,45] In order to determine the factors associated with recurrence, we followed the patients for at least 3 years. The overall prognosis was

Table 3 Results of Univariable and Multivariable Analyses of Ultrasound Features, Immunohistochemical Indexes and PTC Recurrence

Characteristics	Recurrence (n=33)	Non-Recurrence (n=270)	Univariable Analysis		Multivariable Analysis	
			HR (95% CI)	P-value	HR (95% CI)	P-value
Age (years)						
<55 years	17(51.5%)	207(76.7%)	I		I	
≥55 years	16(48.5%)	63(23.3%)	2.836 (1.433–5.614)	0.003	2.258 (1.069–4.770)	0.033
Sex					N/A	
Female	24 (72.7%)	200 (74.1%)	I			
Male	9 (27.3%)	70 (25.9%)	1.077 (0.501–2.317)	0.849		
Size groups						
<10 mm	6 (18.2%)	97 (35.9%)	I		I	
10–20 mm	15 (45.4%)	129 (47.8%)	2.198 (0.779–6.048)	0.127	2.556 (0.869–7.517)	0.088
>20 mm	12 (36.4%)	44 (16.3%)	5.427 (1.934–15.228)	**0.001**	6.339 (1.832–21.929)	**0.004**
Echogenicity					N/A	
Isoechoic/Hyperechoic	3 (9.1%)	10 (3.7%)				
Hypoechoic/Marked hypoechoic	30 (90.9%)	260 (96.3%)	0.377 (0.115–1.237)	0.108		
Border					N/A	
Clear	6 (18.2%)	84 (31.1%)	I			
Obscure	27 (81.8%)	186 (68.9%)	2.444 (0.944–6.331)	0.066		
Margin					N/A	
Regular	9 (27.3%)	124 (45.9%)	I			
Irregular	24 (72.7%)	146 (54.1%)	2.135 (0.992–4.593)	0.052		
Shape					N/A	
Wide than taller	11 (33.3%)	148 (54.8%)	I			
Taller than wide	22 (66.7%)	122 (45.2%)	2.295 (1.113–4.733)	**0.024**		
Microcalcification					N/A	
No	12 (36.4%)	100 (37.0%)	I			
Yes	21 (63.6%)	170 (63.0%)	1.035 (0.509–2.103)	0.925		
Blood flow					N/A	
I–II	16 (48.5%)	183 (67.8%)	I			
III–IV	17 (51.5%)	87 (32.2%)	2.196 (1.110–4.374)	**0.024**		
Capsular invasion						
No	9 (27.3%)	236 (87.4%)	I		I	
Yes	24 (72.7%)	34 (12.6%)	13.976 (6.488–30.107)	**<0.001**	6.915 (2.974–16.078)	**<0.001**
Multifocality						
No	9 (27.3%)	185 (68.5%)	I		I	
Yes	24 (72.7%)	85 (31.5%)	5.281 (2.454–11.366)	**<0.001**	2.503 (1.115–5.618)	**0.026**
Ki-67						
<5%	7 (21.2%)	196 (72.6%)	I		I	
5%-10%	17 (51.5%)	60 (22.2%)	7.071 (2.931–17.058)	**<0.001**	3.631 (1.324–9.961)	**0.012**
>10%	9 (27.3%)	14 (5.2%)	16.070 (5.973–42.237)	**<0.001**	5.343 (1.745–16.365)	**0.003**
CK19					N/A	
<25%	2 (6.1%)	50 (18.5%)	I			
25–50%	24 (72.7%)	177 (65.6%)	3.219 (0.761–13.621)	0.112		
50–75%	4 (12.1%)	31 (11.5%)	3.033 (0.556–16.561)	0.200		
>75%	3 (9.1%)	12 (4.4%)	5.774 (0.964–34.574)	0.055		
p53						
<5%	4 (12.1%)	147 (54.4%)	I		I	

(Continued)

Table 3 (Continued).

Characteristics	Recurrence (n=33)	Non-Recurrence (n=270)	Univariable Analysis		Multivariable Analysis	
			HR (95% CI)	P-value	HR (95% CI)	P-value
≥5%	29 (87.9%)	123 (45.6%)	7.889 (2.773–22.466)	**<0.001**	3.896 (1.252–12.118)	**0.019**
T stage						
T1	5 (15.1%)	212 (78.5%)	1		1	
T2	6 (18.2%)	37 (13.7%)	6.455 (1.970–21.153)	**0.002**	2.687 (0.584–12.352)	0.204
T3	22 (66.7%)	21 (7.8%)	30.480 (11.518–80.660)	**<0.001**	7.220 (2.429–21.467)	**<0.001**
N stage						
N0	1 (3.0%)	177 (65.6%)	1		1	
N1a	32 (97.0%)	93 (34.4%)	52.472 (7.168–384.091)	**<0.001**	9.368 (1.196–73.393)	**0.033**

Note: Bold P-values are statistically significant (P<0.05).
Abbreviations: HR, hazard ratios; CI, confidence interval; N/A, not available.

favorable, and no deaths were recorded. Therefore, we only analyzed the difference in RFS. The Kaplan–Meier analysis showed that Ki-67 5%-10% or >10% and p53 ≥5% were associated with relapse, with recurrence rates of 22.1%, 39.1%, and 19.1%, respectively. Moreover, multiple factors were also confirmed; the most important factor for CLNM was Ki-67 >10%, consistent with previous findings.[14,33] The above conclusions further clarified that proliferative activity is a critical factor in the assessment of PTC recurrence. A positive correlation was observed between tumor size and recurrence or tumor-specific mortality,[1] but no significant difference was detected between the 10–20 and <10 mm groups. Thus, the present study supports the >20-mm threshold used by the AJCC staging. In the present study, T3 tumors and N1a involvement were associated with recurrence. T staging and N staging are recognized prognostic factors for PTC[46,47] and were confirmed in the present study, suggesting the reliability of the research results. Imaging findings (which are macroscopic observations) showed that capsule invasion was consistent with histopathological (microscopic) ETE, and multifocality could potentially cause invasion of the capsule and effectuate histological characteristics of ETE; interestingly, the presence of ETE was related to local recurrence and distant metastasis.[48,49] We also confirmed that capsular invasion and multifocal tumors were independently associated with recurrence. Therefore, ultrasound examination of PTC patients should be focused on the evaluation of the above features. In order to prevent the over-staging of low-risk patients and reduce the excess treatment, the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) staging system adjusted the age threshold from 45 to 55 years.[50] Surprisingly, the results showed that age was not related to CLNM, but it was associated with prognosis. Nevertheless, the predictive value of age for prognosis is yet controversial, as mentioned previously.[51,52]

The present study has some limitations. First, 34.0% and 47.5% of the cases were maximum tumor diameter >10 and 10–20 mm, respectively, while only 18.5% were >20 mm, which might be attributed to a bias in case selection. Second, the World Health Organization (WHO) classifies PTC into classic, follicular, diffuse sclerotic, high cell, and columnar cell subtypes. The degree of invasion of different subtypes of PTC varies,[1] but this could not be analyzed because of the two small numbers of patients in some subtypes. Furthermore, the median follow-up was <5 years, and there is a possibility of occult micrometastases, and may not be sufficient to evaluate the variation in RFS. Third, the detection of the tumor proliferation indexes id valuable in increasing the accuracy of the diagnosis of auxiliary fine-needle aspiration cytology,[53,54] which provides the feasibility for the preoperative acquisition. In this retrospective study, we analyzed the immunohistochemical indicators detected after surgery, and the ultrasound features and immunohistochemical indicators were subjective evaluations.

Conclusion

For patients with PTC and rich blood flow, taller-than-wide shape, multifocality, capsular invasion, p53 ≥5%, Ki-67 >10%, T2 or T3 stages prophylactic CLND might be recommended. Moreover, the age≥55 years, maximum tumor diameter >20 mm, multifocality, capsular invasion, high Ki-67, p53 ≥5%, T3 stage and N1a stage affected the

**Figure 2** Kaplan–Meier curve of RFS in PTC patients. (**A**) Comparison between <55-years-old and ≥55-years-old patients. (**B**) Comparison of tumor maximum diameter <10, 10–20 mm, and >20 mm. (**C**) Comparison of multifocal tumors with single tumors. (**D**) Comparison of tumor invasion and non-invasion. (**E**) Comparison of Ki-67 <5%, Ki-67 5%-10%, and Ki-67 >10%. (**F**) Comparison of p53 <5% and p53 ≥5%. (**G**) Comparison of T1, T2, and T3. (**H**) Comparison of N0 and N1a.

clinical outcome. Such patients would benefit from expanding the scope of surgery that would help avoid the high incidence of complications caused by a second surgery.

Abbreviations

PTC, Papillary thyroid carcinoma; LNM, lymph node metastasis; ETE, extra-thyroid extension; CLNM, central LNM; ATA, American Thyroid Association; CLND, central lymph node dissection.

Data Sharing Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics Approval and Informed Consent

This study was approved by the Ethics Committee of Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Science (No. JDKW-2016-W12). All participants provided written informed consent.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

Disclosure

All authors declare that they have no conflicts of interest for this work.

References

1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2016;26(1):1–133. doi:10.1089/thy.2015.0020
2. Zhang L, Yang J, Sun Q, et al. Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: older patients with fewer lymph node metastases. *Eur J Surg Oncol*. 2016;42(10):1478–1482. doi:10.1016/j.ejso.2016.07.002
3. Strajina V, Dy BM, McKenzie TJ, et al. Treatment of lateral neck papillary thyroid carcinoma recurrence after selective lateral neck dissection. *Surgery*. 2019;165(1):31–36. doi:10.1016/j.surg.2018.04.063
4. Sugitani I, Fujimoto Y, Yamada K, et al. Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. *World J Surg*. 2008;32 (11):2494–2502. doi:10.1007/s00268-008-9711-9
5. Kim KE, Kim EK, Yoon JH, et al. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. *World J Surg*. 2013;37 (2):385–391. doi:10.1007/s00268-012-1826-3
6. Xu JM, Xu HX, Li XL, et al. A risk model for predicting central lymph node metastasis of papillary thyroid microcarcinoma including conventional ultrasound and acoustic radiation force impulse elastography. *Medicine (Baltimore)*. 2016;95(3):e2558. doi:10.1097/MD.0000000000002558
7. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. *Surgery*. 2008;144(6):980–987. doi:10.1016/j.surg.2008.08.035
8. Pisanu A, Reccia I, Nardello O, et al. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. *World J Surg*. 2009;33(3):460–468. doi:10.1007/s00268-008-9870-8
9. Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. *World J Surg*. 2004;28(5):498–501. doi:10.1007/s00268-004-7192-z
10. Na DK, Choi YJ, Choi SH, et al. Evaluation of cervical lymph node metastasis in thyroid cancer patients using real-time CT-navigated ultrasonography: preliminary study. *Ultrasonography*. 2015;34 (1):39–44. doi:10.14366/usg.14030
11. Kim SK, Woo JW, Park I, et al. Computed tomography-detected central lymph node metastasis in ultrasonography node-negative papillary thyroid carcinoma: is it really significant? *Ann Surg Oncol*. 2017;24(2):442–449. doi:10.1245/s10434-016-5552-1
12. Choi YJ, Yun JS, Kook SH, et al. Clinical and imaging assessment of cervical lymph node metastasis in papillary thyroid carcinomas. *World J Surg*. 2010;34(7):1494–1499. doi:10.1007/s00268-010-0541-1
13. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: diagnosis of central and lateral compartment nodal metastases. *Eur J Radiol*. 2019;112:14–21. doi:10.1016/j.ejrad.2019.01.006
14. Miyauchi A, Kudo T, Hirokawa M, et al. Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. *Eur Thyroid J*. 2013;2(1):57–64. doi:10.1159/000347148
15. Denkert C, Loibl S, Müller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. *Ann Oncol*. 2013;24(11):2786–2793. doi:10.1093/annonc/mdt350
16. Koc N, Sahin D, Ayas S. Reevaluation of negative cone biopsy results after a positive cervical biopsy finding. *J Low Genit Tract Dis*. 2013;17(2):154–159. doi:10.1097/LGT.0b013e31825c33f9
17. Li P, Xiao ZT, Braciak TA, et al. Association between Ki67 index and clinicopathological features in colorectal cancer. *Oncol Res Treat*. 2016;39(11):696–702. doi:10.1159/000450623
18. Ahn HK, Jung M, Ha SY, et al. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. *Tumour Biol*. 2014;35(6):5735–5740. doi:10.1007/s13277-014-1760-0
19. Pan DH, Wen DY, Luo YH, et al. The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6051 cases. *Onco Targets Ther*. 2017;10:3261–3276. doi:10.2147/OTT.S135593
20. Khalesi M, Waterhouse M, Whiteman DC, et al. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk. *Int J Dermatol*. 2016;55(10):1096–1105. doi:10.1111/ijd.13276

21. Lee YM, Lee JB. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. *J Int Med Res*. 2013;41(3):825–834. doi:10.1177/0300060513477312

22. Ciaputa R, Nowak M, Kandefer-Gola M, et al. Morphological and immunohistological characteristics of follicular-compact thyroid carcinoma in dog. *Folia Histochem Cytobiol*. 2014;52(2):157–161. doi:10.5603/FHC.2014.0009

23. Bose D, Das RN, Chatterjee U, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. *Indian J Med Paediatr Oncol*. 2012;33(2):107–111. doi:10.4103/0971-5851.99746

24. Paunovic I, Isic T, Havelka M, et al. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. *APMIS*. 2012;120(5):368–379. doi:10.1111/j.1600-0463.2011.02842.x

25. Zhu X, Sun T, Lu H, et al. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. *J Clin Pathol*. 2010;63(9):786–789. doi:10.1136/jcp.2010.076901

26. Kaliszewski K, Diakowska D, Strutynska-Karpinska M, et al. Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region. *Folia Histochem Cytobiol*. 2016;54(4):193–201. doi:10.5603/FHC.a2016.0025

27. Isic Dencic T, Cvejic D, Paunovic I, et al. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. *Med Oncol*. 2013;30(1):362.

28. Mohamed SY, Ibrahim TR, Elbasateeny SS, et al. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis. *Sci Rep*. 2020;10(1):10651. doi:10.1038/s41598-020-67615-0

29. Adler DD, Carson PL, Rubin JM, et al. Doppler ultrasound color flow imaging in the study of breast cancer: preliminary findings. *Ultrasound Med Biol*. 1990;16(6):553–559. doi:10.1016/0301-5629(90)90020-D

30. Kwak JY, Kim EK, Youk JH, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. *Thyroid*. 2008;18(6):609–614. doi:10.1089/thy.2007.0345

31. Kim H, Kim JA, Son EJ, et al. Preoperative prediction of the extrathyroidal extension of papillary thyroid carcinoma with ultrasonography versus MRI: a retrospective cohort study. *Int J Surg*. 2014;12(5):544–548. doi:10.1016/j.ijsu.2014.03.003

32. Dwivedi SS, Khandeparkar SG, Joshi AR, et al. Study of immunohistochemical markers (CK-19, CD-56, Ki-67, p53) in differentiating benign and malignant solitary thyroid nodules with special reference to papillary thyroid carcinomas. *J Clin Diagn Res*. 2016;10(12):EC14–EC19.

33. Matsuse M, Yabuta T, Saenko V, et al. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. *Sci Rep*. 2017;7:41752.

34. Moo TA, McGill J, Allendorf J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. *World J Surg*. 2010;34(6):1187–1191. doi:10.1007/s00268-010-0418-3

35. Giordano D, Valcavi R, Thompson GB, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. *Thyroid*. 2012;22(9):911–917. doi:10.1089/thy.2012.0011

36. Nixon IJ, Wang LY, Ganly I, et al. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. *Br J Surg*. 2016;103(3):218–225. doi:10.1002/bjs.10036

37. Yang Y, Chen C, Chen Z, et al. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. *Clin Endocrinol (Oxf)*. 2014;81(2):282–288. doi:10.1111/cen.12417

38. Bartolotta TV, Midiri M, Galia M, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: initial results. *Eur Radiol*. 2006;16(10):2234–2241. doi:10.1007/s00330-006-0229-y

39. Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. *Sci Rep*. 2015;5(1):7748. doi:10.1038/srep07748

40. Yuan J, Zhao G, Du J, et al. To identify predictors of central lymph node metastasis in patients with clinically node-negative conventional papillary thyroid carcinoma. *Int J Endocrinol*. 2016;2016:6109218. doi:10.1155/2016/6109218

41. Maksimovic S, Jakovljevic B, Gojkovic Z. Lymph node metastases papillary thyroid carcinoma and their importance in recurrence of disease. *Med Arch*. 2018;72(2):108–111. doi:10.5455/medarh.2018.72.108-111

42. Ito Y, Miyauchi A, Kakudo K, et al. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. *World J Surg*. 2010;34(12):3015–3021. doi:10.1007/s00268-010-0746-3

43. Marcello MA, Morari EC, Cunha LL, et al. P53 and expression of immunological markers may identify early stage thyroid tumors. *Clin Dev Immunol*. 2013;2013:846584. doi:10.1155/2013/846584

44. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. *J Clin Endocrinol Metab*. 2006;91(1):313–319. doi:10.1210/jc.2005-1322

45. Kruijff S, Petersen JF, Chen P, et al. Patterns of structural recurrence in papillary thyroid cancer. *World J Surg*. 2014;38(3):653–659. doi:10.1007/s00268-013-2286-0

46. Lang BH, Lo CY, Chan WF, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. *Ann Surg*. 2007;245(3):366–378. doi:10.1097/01.sla.0000250445.92336.2a

47. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Thyroid Carcinoma. Version 2.2020*. Fort Washington: National Comprehensive Cancer Network; 2020.

48. Danilovic DLS, Castroneves LA, Suemoto CK, et al. Is there a difference between minimal and gross extension into the strap muscles for the risk of recurrence in papillary thyroid carcinomas? *Thyroid*. 2020;30(7):1008–1016. doi:10.1089/thy.2019.0753

49. Liu C, Xiao C, Chen J, et al. Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma: a study of 966 patients. *BMC Cancer*. 2019;19(1):622. doi:10.1186/s12885-019-5835-6

50. Brierley JD, Gospodarowicz MK, Wittekind C. *TNM Classification of Malignant Tumours*. 8th ed. Wiley-Blackwell; 2017.

51. Ciobanu Apostol D, Giuşcă SE, Căruntu ID, et al. Relationships between clinicopathological prognostic factors in papillary thyroid microcarcinoma: a refined analysis based on 428 cases. *Int J Clin Exp Pathol*. 2017;10(8):8944–8956.

52. Song J, Yan T, Qiu W, et al. Clinical analysis of risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a retrospective study of 3686 patients. *Cancer Manag Res*. 2020;12:2523–2530. doi:10.2147/CMAR.S250163

53. Mu N, Juhlin CC, Tani E, et al. High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma. *Endocrine*. 2018;61(2):293–302. doi:10.1007/s12020-018-1627-z

54. Lacoste-Collin L, d'Aure D, Bérard E, et al. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls. *Cytopathology*. 2014;25(3):160–169. doi:10.1111/cyt.12128